Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Pfizer, Eisai Launch Lyrica
June 21, 2010
- GL for Non-Clinical Evaluation of Anti-Malignant Tumor Agents Issued
June 21, 2010
- Eplerenone Meets Primary Endpoint Early in PIIIb: Pfizer
June 21, 2010
- Bayer to Expand Packing Line for Chewable Tablets
June 21, 2010
- Clinical Trial Costs Can Be Cut Using iPad: Mr Hasegawa
June 21, 2010
- Lubiprostone Meets Primary Endpoint in PIII in Japan
June 21, 2010
- Asahi Kasei's Pharm Sales to Fall below Target Set in Mid-Term Management Plan
June 21, 2010
- New OTC Drugs Consultation Services Started
June 21, 2010
- Diovan Shows Hypotensive Effects in Elderly Japanese Patients
June 21, 2010
- Rezaltas No. 1 in Both HP, GP Market
June 21, 2010
- Korosho to Consult Medical Societies on 19 Switch OTC Drug Candidates
June 21, 2010
- GenomIdea Receives Grant for Developing DNA Vaccines for Pandemic Flu
June 21, 2010
- Eisai Licenses Netupitant + Palonosetron Combinations from Helsinn in US
June 21, 2010
- Pfizer Oncology to Accelerate Multinational Trials to Eliminate “Drug Lag” VP S. Lowenthal
June 21, 2010
- Risk of Stroke Reduced by Intensified Intervention in Japanese Diabetes Patients
June 21, 2010
- Ranbaxy Launches Prasugrel in India
June 21, 2010
- Roche Aims to Apply for 5 Anticancer Agents by 2013: VP Hal Barron
June 21, 2010
- Radiotherapy May Be Omitted in Elderly Breast Cancer Patients
June 21, 2010
- High % of Prescriptions Still Prohibit Generic Substitution: Nihon Chouzai
June 21, 2010
- Merck Serono to Accelerate Development of Personalized Cancer Treatments: EVP W. Wein
June 21, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…